GlassScriptPhysician profile
Mary E Evans
NPI 1508948340
$3,597.03
in general payments reported to CMS, 2019-2025
35 companies · $959 in 2025
The $959 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $157 · 2023: $820 · 2024: $1,661 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,360 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.43 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $405.29 | 2024-2025 | Farxiga, Airsupra, Lokelma |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.91 | 2023-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $313.59 | 2023-2025 | Gemtesa |
| Abbvie INC. | $309.74 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $202.59 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $174.04 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Alkermes, INC. | $156.61 | 2022 | |
| Astellas Pharma US INC | $151.75 | 2023-2024 | Veozah |
| Amgen INC. | $131.72 | 2023-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $124.69 | 2023-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $109.79 | 2024-2025 | |
| Glaxosmithkline, LLC. | $94.89 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $90.63 | 2023-2024 | Trintellix |
| Exact Sciences Corporation | $90.59 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $87.82 | 2024 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $75.58 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $73.92 | 2023-2024 | Quviviq |
| Corcept Therapeutics | $72.42 | 2024-2025 | Korlym |
| Abbott Laboratories | $65.92 | 2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $59.98 | 2024 | Yupelri |
| Esperion Therapeutics, INC. | $50.30 | 2024-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $50.03 | 2024 | Verquvo, Capvaxive, Gardasil 9 |
| Dexcom, INC. | $42.08 | 2024-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $37.98 | 2025 | Auvelity |
| Pfizer INC. | $33.97 | 2024-2025 | |
| Shield Therapeutics INC | $33.34 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.79 | 2023-2024 | Xifaxan |
| Neurocrine Biosciences, INC. | $29.70 | 2023-2024 | Ingrezza |
| Radius Health, INC. | $22.24 | 2025 | Tymlos |
| Neos Therapeutics, LP | $21.68 | 2024 | Adzenys Xr-Odt |
| Phathom Pharmaceuticals, INC. | $17.61 | 2025 | Voquezna |
| Viatris Specialty LLC | $17.53 | 2025 | Yupelri |
| Acadia Pharmaceuticals INC | $15.44 | 2025 | Nuplazid |
| Evoke Pharma, INC. | $15.20 | 2023 | Gimoti |
| Antares Pharma, INC. | $14.67 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.